ADL-T2 10mg

Research Overview

Tirzepatide is a synthetic 39-amino acid peptide analogue featuring a non-standard α-aminoisobutyric acid (Aib) residue at position 1, conferring resistance to dipeptidyl peptidase-4 (DPP-4) degradation. It is structurally classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist. The peptide backbone is conjugated at lysine-26 via a γ-glutamic acid linker incorporating two mini-PEG (OEG) spacers and a C18 fatty diacid moiety, enabling reversible albumin binding and an extended plasma half-life of approximately five days in vivo. Researchers study tirzepatide to investigate the synergistic intracellular signaling dynamics arising from simultaneous GIPR and GLP-1R activation, including cAMP accumulation, β-arrestin recruitment, and downstream effects on pancreatic β-cell function, adipose tissue lipolysis, and hypothalamic energy-sensing pathways. Current research areas include comparative receptor pharmacology, biased agonism profiling, body composition modulation mechanisms, and hepatic lipid metabolism.